We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Comeback for Juno (JUNO) Stock? FDA Lifts Clinical Hold
Read MoreHide Full Article
Is immuno-oncology focused Juno Therapeutics, Inc. , set for a comeback? The company, which saw its shares falling 31.9% last week, looks poised for a recovery with the FDA removing the clinical hold on its pivotal phase II study (ROCKET) on JCAR015.
Why Was ROCKET on Clinical Hold?
The FDA had placed the ROCKET study on clinical hold last week after two patients died within a week due to severe neurotoxicity following the recent addition of fludarabine to the pre-conditioning regimen (Read more: Juno Suffers Setback, Pivotal Study on Clinical Hold).
Juno had proposed the continuation of the study using JCAR015 with cyclophosphamide pre-conditioning alone. The study is being conducted in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia (r/r ALL).
Shares Up in After-Hours Trading
Juno’s shares were up 24.2% in after-hours trading following the company’s announcement that the FDA has lifted the clinical hold on the study which will continue under a revised protocol – the study will continue enrollment using JCAR015 with cyclophosphamide pre-conditioning alone.
While the lifting of the clinical hold is a huge boost for the stock, investors will have to wait for the company’s earnings call to get more details on expected regulatory filing timelines for the candidate. Juno was earlier looking to gain accelerated FDA approval in 2017 but timelines were pushed back with the clinical hold being announced. However, now that the study has resumed, we await more clarity on the company’s plans for filing for approval.
Meanwhile, the lifting of the clinical hold has boosted the stock of other immuno-oncology focused companies like Kite Pharma, Inc. and bluebird bio, Inc. (BLUE - Free Report) as well, which were up in after-hours trading.
Juno is a Zacks Rank #4 (Sell) stock. Merrimack Pharmaceuticals, Inc. (MACK - Free Report) is a better-ranked stock in the healthcare sector with a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Comeback for Juno (JUNO) Stock? FDA Lifts Clinical Hold
Is immuno-oncology focused Juno Therapeutics, Inc. , set for a comeback? The company, which saw its shares falling 31.9% last week, looks poised for a recovery with the FDA removing the clinical hold on its pivotal phase II study (ROCKET) on JCAR015.
Why Was ROCKET on Clinical Hold?
The FDA had placed the ROCKET study on clinical hold last week after two patients died within a week due to severe neurotoxicity following the recent addition of fludarabine to the pre-conditioning regimen (Read more: Juno Suffers Setback, Pivotal Study on Clinical Hold).
Juno had proposed the continuation of the study using JCAR015 with cyclophosphamide pre-conditioning alone. The study is being conducted in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia (r/r ALL).
Shares Up in After-Hours Trading
Juno’s shares were up 24.2% in after-hours trading following the company’s announcement that the FDA has lifted the clinical hold on the study which will continue under a revised protocol – the study will continue enrollment using JCAR015 with cyclophosphamide pre-conditioning alone.
JUNO THERAPEUTC Price
JUNO THERAPEUTC Price | JUNO THERAPEUTC Quote
While the lifting of the clinical hold is a huge boost for the stock, investors will have to wait for the company’s earnings call to get more details on expected regulatory filing timelines for the candidate. Juno was earlier looking to gain accelerated FDA approval in 2017 but timelines were pushed back with the clinical hold being announced. However, now that the study has resumed, we await more clarity on the company’s plans for filing for approval.
Meanwhile, the lifting of the clinical hold has boosted the stock of other immuno-oncology focused companies like Kite Pharma, Inc. and bluebird bio, Inc. (BLUE - Free Report) as well, which were up in after-hours trading.
Juno is a Zacks Rank #4 (Sell) stock. Merrimack Pharmaceuticals, Inc. (MACK - Free Report) is a better-ranked stock in the healthcare sector with a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>